683 Capital Management’s Applied Genetic Technologies Corporation AGTC Stock Holding History

683 Capital Management’s Portfolio AGTC Stock Details AGTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-175,000	Closed	-$716K	–	262
2020 Q4	$716K	Sell	175,000 -189,299	-52%	-$930K	0.03%	127
2020 Q3	$1.77M	Sell	364,299 -120,701	-25%	-$659K	0.13%	86
2020 Q2	$2.69M	Sell	485,000 -50,000	-9%	-$229K	0.22%	71
2020 Q1	$1.75M	Sell	535,000 -22,834	-4%	-$120K	0.21%	74
2019 Q4	$2.52M	Hold	557,834	–	–	0.29%	56
2019 Q3	$2.32M	Buy	557,834 +357,834	+179%	+$1.29M	0.26%	59
2019 Q2	$758K	Hold	200,000	–	–	0.07%	106
2019 Q1	$838K	Hold	200,000	–	–	0.08%	98
2018 Q4	$498K	Hold	200,000	–	–	0.03%	122
2018 Q3	$1.46M	Sell	200,000 -100,000	-33%	-$438K	0.09%	91
2018 Q2	$1.11M	Hold	300,000	–	–	0.08%	97
2018 Q1	$1.16M	Buy	300,000 +83,968	+39%	+$353K	0.1%	93
2017 Q4	$778K	Buy	+216,032	New	+$816K	0.07%	110

Other funds holding AGTC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

683 Capital Management's AGTC Position: Q1 2021 in Review

683 Capital Management sold out of Applied Genetic Technologies Corporation (AGTC) in Q1 2021, closing a stake of 175,000 shares — an estimated $716K sold.

683 Capital Management first reported a position in AGTC in Q4 2017 and held it in 13 quarters. The position peaked at $2.69M in Q2 2020. 82 funds tracked by Wall St. Rank hold AGTC as of Q1 2021.

683 Capital Management reported no remaining Applied Genetic Technologies Corporation position as of Q1 2021 after selling out during the quarter.
683 Capital Management sold 175,000 Applied Genetic Technologies Corporation shares in Q1 2021, an estimated $716K.
683 Capital Management first reported a position in Applied Genetic Technologies Corporation in Q4 2017 and held it in 13 quarters.
683 Capital Management's Applied Genetic Technologies Corporation position peaked at $2.69M in Q2 2020.
82 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q1 2021.

Based on 683 Capital Management's 13F filing for Q1 2021, filed 17 May 2021.